Abstract | BACKGROUND: METHODS: RESULTS:
Galantide significantly reduced AP-induced hyperenzymaemia by 39-45%. Octreotide alone, or in combination with galantide, did not significantly alter AP-induced hyperenzymaemia. Plasma enzyme activity in the control groups was comparable with pre-treatment activity. Galantide and octreotide administered individually reduced MPO activity by 79% and 50%, respectively; however their combination was without effect. Galantide, octreotide and their combination significantly reduced the percentage of abnormal acinar cells by 28-45%. CONCLUSIONS: Treatment with galantide alone ameliorated most of the indices of AP studied, whereas treatment with octreotide reduced pancreatic MPO activity and acinar cell damage. Combining the two peptides appears to negate their individual benefits, which suggests an interaction in their mechanism of action.
|
Authors | Savio G Barreto, Colin J Carati, Ann C Schloithe, James Toouli, Gino T P Saccone |
Journal | HPB : the official journal of the International Hepato Pancreato Biliary Association
(HPB (Oxford))
Vol. 12
Issue 6
Pg. 403-11
(Aug 2010)
ISSN: 1477-2574 [Electronic] England |
PMID | 20662791
(Publication Type: Comparative Study, Journal Article, Research Support, Non-U.S. Gov't)
|
Chemical References |
- Biomarkers
- galantide
- Substance P
- Galanin
- Ceruletide
- Peroxidase
- Lipase
- Amylases
- Octreotide
|
Topics |
- Acute Disease
- Amylases
(blood)
- Animals
- Biomarkers
(blood)
- Ceruletide
- Disease Models, Animal
- Drug Therapy, Combination
- Galanin
(analogs & derivatives, pharmacology)
- Lipase
(blood)
- Male
- Mice
- Octreotide
(pharmacology)
- Pancreas
(drug effects, enzymology, pathology)
- Pancreatitis
(chemically induced, enzymology, pathology, prevention & control)
- Peroxidase
(metabolism)
- Substance P
(analogs & derivatives, pharmacology)
- Time Factors
|